SNY SNY
Company Profile ↓Company Overview
SNY (SNY) is a publicly traded company listed on with a market capitalization of $52.17B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 13.4.
Maintains a net profit margin of 16.7%.
Carries low leverage with a debt-to-equity ratio of 0.28.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $46.72B (+5.5% YoY); net profit $7.81B.
- Trailing 12 Months Year-on-year growth — revenue +5.5%, earnings +40.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.8%, profit CAGR -2.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.82% |
| 1 Year: | 5.49% |
Compounded Profit Growth
| 5 Years: | -2.27% |
| 1 Year: | 40.52% |
Stock Price Performance
| 1 Year: | -3.42% |
| 6 Months: | -4.92% |
| 3 Months: | -1.34% |
| 1 Month: | -0.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.37 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -2.3% CAGR over 5 years.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 10.73B | 13.17B | 12.21B | 11.24B | 12.30B |
| Cost of Revenue | - | 2.99B | 3.41B | 3.76B | 3.14B | 3.02B |
| Gross Profit | - | 7.74B | 9.76B | 8.45B | 8.11B | 9.28B |
| Operating Expenses | - | 6.03B | 5.97B | 6.82B | 5.84B | 6.90B |
| Operating Income | - | 1.71B | 3.79B | 1.63B | 2.27B | 2.38B |
| EBITDA | - | 1.89B | 4.20B | -341.00M | 2.72B | 1.68B |
| Interest Expense | - | 87.00M | 227.00M | 38.00M | 178.00M | 287.00M |
| Pretax Income | - | 1.42B | 3.51B | -917.00M | 2.00B | 837.00M |
| Tax Provision | - | 230.00M | 680.00M | -348.00M | 420.00M | 451.00M |
| Net Income | - | 3.94B | 2.80B | -801.00M | 1.61B | 343.00M |
| Diluted EPS | - | 1.62 | 1.15 | -0.33 | 0.67 | 0.14 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 40.56B | 41.62B | 44.29B | 46.72B |
| Cost of Revenue | - | 11.88B | 12.63B | 13.21B | 13.05B |
| Gross Profit | - | 28.68B | 28.99B | 31.08B | 33.67B |
| Operating Expenses | - | 17.75B | 20.30B | 22.16B | 24.07B |
| Operating Income | - | 10.93B | 8.69B | 8.92B | 9.60B |
| EBITDA | - | 13.51B | 11.32B | 10.99B | 12.48B |
| Interest Expense | - | 465.00M | 643.00M | 704.00M | 626.00M |
| Pretax Income | - | 9.94B | 6.25B | 6.70B | 6.17B |
| Tax Provision | - | 1.91B | 1.02B | 1.20B | 1.04B |
| Net Income | - | 8.37B | 5.40B | 5.56B | 7.81B |
| Diluted EPS | - | 2.69 | 2.15 | 2.29 | 3.19 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 126.72B | 126.46B | 132.80B | 126.81B |
| Current Assets | 34.11B | 30.67B | 42.59B | 30.95B |
| Cash & Equivalents | 12.74B | 8.71B | 7.44B | 7.66B |
| Inventory | 8.96B | 9.67B | 9.43B | 10.21B |
| Receivables | 8.42B | 8.43B | 7.68B | 8.41B |
| Total Liabilities | 51.57B | 52.11B | 54.94B | 55.09B |
| Current Liabilities | 23.97B | 24.21B | 29.16B | 28.34B |
| Long Term Debt | 14.86B | 14.35B | 11.79B | 14.25B |
| Total Debt | 21.21B | 18.42B | 17.91B | 20.33B |
| Total Equity | 74.78B | 74.04B | 77.51B | 71.38B |
| Shares Outstanding | 1.27B | 1.26B | 1.26B | 1.22B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 10.53B | 10.26B | 9.08B | 10.75B |
| Investing Cash Flow | - | -2.08B | -6.20B | -4.41B | -2.45B |
| Financing Cash Flow | - | -5.82B | -8.05B | -5.76B | -8.21B |
| Capital Expenditure | - | -2.10B | -2.91B | -3.19B | -3.54B |
| Free Cash Flow | - | 8.42B | 7.35B | 5.89B | 7.21B |
| Net Change in Cash | - | 2.63B | -3.99B | -1.26B | 263.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 70.7% | 69.7% | 70.2% | 72.1% |
| Operating Margin % | - | 26.9% | 20.9% | 20.1% | 20.5% |
| Net Margin % | - | 20.6% | 13.0% | 12.6% | 16.7% |
| ROE % | - | 11.2% | 7.3% | 7.2% | 10.9% |
| ROCE % | - | 10.6% | 8.5% | 8.6% | 9.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SNY
Mets Notes: Kodai Senga to be moved back into bullpen, Robert Stock to get another start - SNY
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxOWC1TTEcwb2ozVzI4R01yRHc2eU9kWlFlNGhrZVBGcy02bkZsSmZvRm9NWlhUaVRUcTgyMHFpdWUyUEI1ODl3enNOaGJfMi1FNUtpQ0pfazI0OWxHTDBnRzVKQ0I2c3cyV3ZtMHM1Q0pXRl91eEtlSGFWVk5NRzVYZUpadWlmUQ?oc=5" t…
Sanofi SA (SNY) Stock Down 4.5% -- Now Undervalued? GF Score: 70/100 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxPRVNGbnhZekgwVFNTYUY2akFFVjUtcV9nWXQxYi1sZTd3V1phRkpNRnB6NFRNd1dIRFFVOW13bHRZNTREZ25jcUxfamVwMERuNHMyMWJiVEtBMXFJelVVUElpV3pZSmV0T2ZaSXdQMnpoc1J3RTRuMmpVUEtqUzJjdVloZ3l5ekZhREYya1…
Is Sanofi (SNY) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPUm9OSklUSEI4V0UzM2lINlVURXRDSjItVTlULW9nNDVZdjJhOVJkU0xjbFQ0R0JKcFh3U2FCOUcyZko4TFI0TWZJMTcxZy16dnFhZElZdzNGWDBvZE1wUS04RFRMb0Rkd0hSV0EyQWh4SGp6Z0E2OVFNZmF2N2Q1VkREdlpHUkp1V05Tek…
Why Sanofi Stock Is Falling Thursday - Sanofi (NASDAQ:SNY) - Benzinga
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPcU0ycncxcjM5Wmo4YldLZDRMTHZTa0s3cDdydkkzMzFrZTVRN3pacWZQVjczWWJpckZjNGxaYkUzOXB3ZHNTNVBUamFKOUFlU2RKX0lidHc0ZmZRTko2TTVFSG4zXzlFOGpHQUdpbmpZOXEyUnFwUkdSOGdDZ3g3Uk41QVpLRk5vOTJWMX…
Robert Stock 'earned the right' to be in Mets' rotation conversation with impressive MLB return - SNY
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxQcGJidnlvc2ZfazlYZzVzeW8wOW04MnhHYm1EWXlvQ19UMmZFeU1IcW0wSTJnUU9VNDVFMGstRUVkaWdxUmQwdDZFanA4N0lCbWw4M3FBdEZIS1BLTHdfUE1ONzJkd2ZCSVJVR3M3NW1CZ3FZcTJMSzJWNWJFNnRmcDhLT2M2ZFVOSEdsX2…
Sanofi Slides After Q2 as Investors Focus on Pipeline Cuts Despite Higher 2026 Outlook - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPSU05cEVBbnZFbGQ4TlJiYWdwTl8zTzhTM1JFSXdVTXduNFY1NEJiaU53ZDFzeEwxTGdWaENMN1lNRnBsUFg1SHlDaml6aGpCdWprQmE3clpVenYycEF1N3dhdzdpNVlFSmw3Yks0SGYzMnlYck8wdHE1WDdMVVd2V2dnQUNuOGZBWnFxdW…
SNY — Frequently Asked Questions
What is the current share price of SNY?
As of 2026-08-05 17:25 PDT, SNY trades at $42.78 on NASDAQ/NYSE. Its 52-week range is $41.31 to $49.59.
What is the market capitalisation of SNY?
SNY has a market capitalisation of $52.17B on NASDAQ/NYSE.
What is the P/E ratio of SNY?
SNY trades at a trailing price-to-earnings (P/E) ratio of 13.43. Its price-to-book (P/B) ratio is 0.73.
What is the return on equity (ROE) of SNY?
SNY has a return on equity (ROE) of 10.95%. Its return on capital employed (ROCE) is 9.75%.
Is SNY a good stock to buy?
This page provides a data-driven analysis of SNY, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.